DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
-
2,4-Diamino-6-hydroxypyrimidine (HB0070)
Description:GTP cyclohydrolase I (GCH1) inhibitor
Purity:>98%
-
-
5,7-Dichlorokynurenic acid (HB0078)
Description:Potent, selective, competitive glycine site NMDA receptor antagonist
Purity:>98%
-
-
Dihydrochlamydocin (HB3874)
Description:Phytotoxin. Derivative of the HDAC inhibitor chlamydocin.
Purity:>95%
-
Dihydroergocristine mesylate (HB1611)
Description:5-HT antagonist. Also partial agonist at adrenergic and dopaminergic receptors.
Purity:>98%
-
Dihydroergotamine mesylate (HB1612)
Description:Partial α-adrenergic agonist, partial D2 agonist and 5-HT antagonist
Purity:>98%
-
